LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (AMEX: BPA) today announced that it and Pantarhei Bioscience B.V., a Netherlands-based pharmaceutical company have initiated a Phase II human clinical trial of a new oral contraceptive. BioSante will co-fund the development of the oral contraceptive up to $1.0 million. Pantarhei will be responsible for all additional expenses to develop and market the product.
